NCT07324278

Brief Summary

This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
81

participants targeted

Target at P25-P50 for not_applicable cardiovascular-diseases

Timeline
52mo left

Started Feb 2026

Longer than P75 for not_applicable cardiovascular-diseases

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress14%
Feb 2026Dec 2030

First Submitted

Initial submission to the registry

December 23, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 7, 2026

Completed
26 days until next milestone

Study Start

First participant enrolled

February 2, 2026

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2030

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2030

Last Updated

August 25, 2026

Status Verified

August 1, 2026

Enrollment Period

4.7 years

First QC Date

December 23, 2025

Last Update Submit

August 21, 2026

Conditions

Cardiovascular DiseasesCerebrovascular DisordersStroke

Keywords

RehabilitationMirror Therapy

Outcome Measures

Primary Outcomes (1)

  • Fugl-Meyer Assessment

    Baseline, 2 weeks, 4 weeks, and 3 months post-intervention.

Secondary Outcomes (8)

  • Grip and pinch power

    Baseline, 4 weeks, and 3 months post-intervention.

  • Revised Nottingham Sensory Assessment

    Baseline, 4 weeks, and 3 months post-intervention.

  • Berg Balance Scale

    Baseline, 4 weeks, and 3 months post-intervention.

  • Motor Activity Log

    Baseline, 4 weeks, and 3 months post-intervention.

  • ABILHAND Questionnaire

    Baseline, 4 weeks, and 3 months post-intervention.

  • +3 more secondary outcomes

Study Arms (3)

High-dose enhanced mirror priming group

EXPERIMENTAL
Behavioral: Mirror primingBehavioral: Conventional therapy

Low-dose enhanced mirror priming group

EXPERIMENTAL
Behavioral: Mirror primingBehavioral: Conventional therapy

Active control group

ACTIVE COMPARATOR
Behavioral: Conventional therapy

Interventions

Mirror primingBEHAVIORAL

During the mirror priming process, the movement images of the participant's unaffected limb are mirrored to the affected side to provide visual feedback.

High-dose enhanced mirror priming groupLow-dose enhanced mirror priming group
Conventional therapyBEHAVIORAL

Conventional therapy is individualized and may include impairment-oriented, shaping, or whole-task practice.

Active control groupHigh-dose enhanced mirror priming groupLow-dose enhanced mirror priming group

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A first-ever unilateral stroke ≥3 months
  • Age between 20 and 80 years
  • Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score ≥ 10
  • No severe spasticity in any joints of the affected arm
  • Ability to follow the instructions
  • No participation in other studies during the study period
  • Willingness to provide informed written consent.

You may not qualify if:

  • Serious medical problems or poor physical conditions that might be detrimental to study participation.
  • Received or planned botulinum toxin injections within 3 months prior to or during the trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

E-Da Hospital

Kaohsiung City, Yanchao District, 82445, Taiwan

RECRUITING

MeSH Terms

Conditions

Cardiovascular DiseasesStrokeCerebrovascular Disorders

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular Diseases

Central Study Contacts

Yi-chun Li, PhD

CONTACT

+886-7-6151100joyjoyfish@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 23, 2025

First Posted

January 7, 2026

Study Start

February 2, 2026

Primary Completion (Estimated)

September 30, 2030

Study Completion (Estimated)

December 31, 2030

Last Updated

August 25, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations

TW(1)